Biogennix Publishes Study of Advanced Bone Graft Material

Biogennix has published a scientific study characterizing the advanced properties of its TrelCor bone graft material.
 
The study, titled “Characterization of an Advanced Bone Graft Material with a Nanocrystalline Hydroxycarbanoapatite Surface and Dual Phase Composition,” was published in the Journal of Biomedical Materials Research – Part B: Applied Biomaterials.
 
The study confirmed the company’s dual phase composition and a nanostructured HCA. Further testing assessed various bone graft properties like bioactivity and in vivo stimulation of stem cells, demonstrating robust bioactive response and capability of stimulation.
 
The findings ultimately underscore efficacy in actively stimulating bone formation response, which the company said leads to TrelCor’s outperformance of traditional, first-generation bone graft materials.
 
TrelCor has over 75,000 successful implantations to date.
 
“The TrelCor characterization study demonstrated that a bone formation response in synthetic graft materials can be positively impacted by modifying a material’s composition and surface structure,” said Dr. Mark Borden, Ph.D., the study’s lead author and chief scientific officer at Biogennix. “These properties form the foundation of TrelCor’s advanced technology, found in Biogennix’s entire line of bone graft products.”
 
Last month, the company earned U.S. Food and Drug Administration (FDA) nods to expand the indication of its Agilon Moldable and Morpheus Moldable bone grafts to use in the interverterbral disc space as an autograft extender, with an FDA-cleared interbody implant for use with a bone void filler.